Program
LY4515100
A development code. Also written as “LY4515100 via SAD”, “LY4515100 via MAD” and “[¹⁴C]-LY4515100 Oral Solution”.
In Eli Lilly's pipeline, Nav1.8 inhibitor
. Its studies are mostly in Acute Pain, led by Eli Lilly.
Furthest: phase 2, since Mar 30, 20263 company-led studies, 3 open or runningNext primary completion: Nov 2026 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Eli Lilly | 33 open or running | phase 2since Mar 30, 2026 | Jan 6, 2026 | Nov 2026phase 2 · NCT07511816 |
- Named in Eli Lilly’s own pipeline as
Nav1.8 Inhibitor (SM)
, phase 2, as of Oct 29, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 6, 2026First study: phase 1 study in HealthyFirst studyNCT07339722 · 209 planned · United States
- Mar 30, 2026Phase 2 study in Acute PainPhase 2 reachedNCT07511816 · 212 planned · United States
- Oct 5, 2026Phase 1 study in HealthyNCT07867327 · 16 planned · United States
Ahead
- Nov 2026Primary completion: phase 2 study in Acute PainNCT07511816
- Dec 2026Primary completion: phase 1 study in HealthyNCT07867327
- Mar 2027Primary completion: phase 1 study in HealthyNCT07339722
TargetBeta
“Nav1.8 inhibitor”the company's pipeline, read by Claude · source
Other programs on SCN10A
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Lidocainerule | Keenova Therapeutics | phase 4 | 63 |
| Lamotriginerule | GlaxoSmithKline | phase 4 | 61 |
| Carbamazepinerule | grin-therapeutics-inc | phase 4 | 21 |
| Dronedaronerule | Sanofi | phase 4 | 18 |
| chloroprocainerule | sintetica-sa | phase 4 | 8 |
| Riluzolerule | Sanofi | phase 4 | 6 |
| Prilocainerule | Haisco Pharmaceutical Group | phase 4 | 2 |
| Carticainerule | Laboratoires Thea | phase 4 | 1 |
| Ropivacainerule | painreform-ltd | phase 3 | 17 |
| Phenytoinrule | Viatris | phase 3 | 10 |
| rufinamiderule | Eisai | phase 3 | 7 |
| HRS-2129 | Jiangsu HengRui Medicine | phase 3 | 7 |
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07867327Healthy · United States | 1 | Not yet recruiting | Dec 2026 | 16 |
| NCT07511816Acute Pain · United States | 2 | Recruiting | Nov 2026 | 212 |
| NCT07339722Healthy · United States | 1 | Recruiting | Mar 2027 | 209 |
How it is read
Names in the registry
- “LY4515100”, 2 entries
- “LY4515100 via SAD”, 1 entry
- “LY4515100 via MAD”, 1 entry
- “[¹⁴C]-LY4515100 Oral Solution”, 1 entry
- “LY4515100 Tablet”, 1 entry
Codes read as this program: LY4515100.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.